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See Articles, pages 378–387 and pages 388–398Acute liver failure (ALF) is a relatively uncommon disease usually
affecting young people without preexisting liver disease. Its clin-
ical spectrum includes not only severe derangement of liver func-
tion, but also multi-organ failure and a high risk of sepsis,
explaining the strong association between ALF and mortality that
exceeds 50% [1]. Liver transplantation is the only therapeutic
approach that has shown a survival beneﬁt in patients with sev-
ere ALF. However, the shortage of organs for transplantation or
the existence of contraindications limits the applicability of the
procedure. In addition, the need of long-life immunosuppressive
therapy in these young patients associates a relevant long-term
morbidity and mortality. On the other hand, when spontaneous
resolution occurs, the liver usually recovers completely.
Therefore it is not surprising that during the last decades, several
attempts of providing temporary support of ALF patients have
been described. In this context, the development of extracorpo-
real liver support devices would be important for maintaining
the patient’s condition until the spontaneous recovery of liver
function occurs or until an organ becomes available. From a the-
oretical perspective, an effective extracorporeal liver support sys-
tem should replace three major functions of the liver:
detoxiﬁcation, biosynthesis and regulation. In the setting of
ALF, the main goals would be to remove putative toxins prevent-
ing further aggravation of liver failure, to stimulate liver regener-
ation and to improve the pathophysiological features of ALF [2].
Toxin removal by high volume plasmapheresis has been tested
with some evidence of success, however it is difﬁcult to draw
conclusions on this approach as the single study performed in
ALF has so far only been presented in abstract form [3].
Clinically, the goal should be to provide liver and support for
other organs with the aim of avoiding transplantation or bridging
the patient to the procedure in the best possible condition.
Extracorporeal liver support systems clinically tested fall into
two main categories: (i) the purely artiﬁcial systems that are
based on the principles of adsorption and ﬁltration and are aimed
to remove circulating toxins by using a variety of membranes and
adsorbents; and (ii) the bioartiﬁcial systems that are hybrid
devices that incorporate liver cells/hepatocytes in order toJournal of Hepatology 20
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failing synthetic liver function [4].
Two large randomized trials speciﬁcally addressing the role of
extracorporeal liver support in ALF have been published in the
past years, one of them using a purely artiﬁcial device based in
albumin dialysis (MARS) [5] and the other with a bioartiﬁcial
device based on porcine liver cells (Hepat-assist) [6]. The endpoint
of both trials was survival. Although mortality was lower in
the experimental arm in both cases, the differences were
non-signiﬁcant. The Hepat-assist trial, including patients with
fulminant and subfulminant liver failure as well as patients with
primary non-function, was prematurely stopped due to futility
although a post-hoc analysis showed a survival beneﬁt in the
subgroup of patients with fulminant or subfulminant liver failure.
In the MARS trial, the high early transplantation rate could have
had a confounding effect in determining the true level of efﬁcacy.
Therefore, the potential role of extracorporeal liver support
remains controversial. From a pathophysiologic point of view, it
is possible to speculate that the efﬁcacy of these devices in terms
of providing an adequate liver support was insufﬁcient, which
suggests that more efﬁcacious devices may have a greater impact
in biology and in clinical outcomes of ALF patients. In this issue of
the Journal of Hepatology, two studies have evaluated two differ-
ent approaches in the treatment of an experimental model of ALF
induced by the administration of D-Galactosamine (GALN) in
large animals (mini-pigs) (Table 1).
It is interesting to note that both groups have elected to use
the same mechanism of inducing ALF in their large animal model.
The GALN model is well established and known to have a variety
of effects beyond simply inducing hepatocyte damage. Although
the GALN model may not be exactly representative of human
ALF, it has the advantage (as demonstrated in both studies) of
good reproducibility, which is important in keeping control of
group sizes for both ethical and ﬁnancial considerations. One fea-
ture of GALN toxicity is the substantial sensitization of the sys-
tem to bacterial lipopolysaccharides (endotoxins) [7]. As such,
the model can be considered to potentiate the effects of circula-
tory disturbances and dysfunction of secondary organs that
may be observed subsequently to ALF.
The fact that both extracorporeal systems show signiﬁcant
improvements in survival over a relatively short period of time
suggests that the primary beneﬁcial effect in these models is
detoxiﬁcation. The capacity of a device for removal of toxins
has always been a key consideration in the concept and design15 vol. 63 j 303–305
Table 1. An outline of the two different approaches followed by Glorioso et al. & Zhou et al.
Glorioso et al. Zhou et al. 
Animal model D-galactosamine induced ALF in pigs
Liver support approach BAL support based on porcine hepatocyte 
spheroids
Study groups Control
Non-cell based artificial liver support
BAL with porcine hepatocyte spheroids
Major outcome Improve survival in BAL based system
Minor outcomes Prevention of cerebral manifestations of 
ALF
Less vasopressor requirements
Major concerns Risk of zoonosis
D-galactosamine induced ALF in pigs
Low-volume plasma exchange with plasma filtration 
and adsorption
Control
Plasma filtration and adsorption
Low-volume plasma exchange
Low-volume plasma exchange with plasma filtration 
adsorption
Improve survival in low-volume plasma exchange with 
plasma filtration adsorption
Improvement in liver tests and attenuation of 
inflammatory response
Improvement in liver regeneration
Filter efficiency
ALF, acute liver failure; BAL, bioartiﬁcial liver.
Editorialof previous systems. For those based on adsorbent columns, the
question of saturation of the materials and hence the effective
treatment times have been raised repeatedly [8]. Although the
system reported by Zhou et al. utilizes a sorbent component to
the system, its novel combination with plasma exchange appears
to offer improved functionality and capacity to remove toxic
metabolites. In the study by Glorioso et al., it is the functional bio-
mass rather than sorbent capacity that appears to be the key ele-
ment for an effective therapy. This study uses primary cells rather
than cultured cell lines which may also prove to be signiﬁcant in
the future development of bioartiﬁcial systems due to concerns
over the amount of metabolic function retained by transformed
cells [8]. Neither study indicates speciﬁcally which toxins are tar-
geted and removed by their extracorporeal devices, but instead
show a subsequent reduction in inﬂammatory markers such as
cytokines and ammonia. Although there are many possible
sources of inﬂammation that might be removed, considering that
the GALN model is known to have enhanced sensitivity to bacte-
rial endotoxins it may be reasonable to consider than these sys-
tems have some capacity to remove (or metabolise) these
substances.
The duration of therapy also appears to be a determining fac-
tor for a positive outcome. In the spheroid hepatocyte system a
single 24 hour treatment was found to be more effective with
repeated 6 hour therapy sessions. This would suggest that the
ability to provide continual support to an ALF patient rather than
intermittent detoxiﬁcation provides a more conducive environ-
ment for hepatic recovery/regeneration. The study of Zhou et al.
did not examine variable treatment sessions, but the timing of
duration of the therapy are likely to be integral to the success
of the device. In both models the treatment was started after it
could be shown that a threshold for ALF had been passed. It could
be considered that in a clinical setting, the earlier that treatment
could be initiated the more likely it is that pre-insult liver func-
tion could be restored.
It should be noted that both systems include the potential to
supplement the subjects’ albumin, either by introduction of
exogenous plasma or by de novo synthesis by the hepatocytes.
It has become evident in recent years that albumin performs a
number of functions beyond that of plasma volume regulation,
indicating that the design of future extracorporeal systems304 Journal of Hepatology 201should include the provision to renew or replace the patient’s
own protein [9]. Whether the design of new systems should
include the provision to additionally supplement the patients’
albumin to a nominal therapeutic level remains an open ques-
tion. Though it should be considered that increasing the total
metabolic transport capacity for the patient by increasing albu-
min levels should improve the rate at which harmful metabolites
are carried to an extracorporeal device for detoxiﬁcation.
Both groups indicate that they wish to progress to human
studies, though as has been stated above [4], studies in ALF are
complicated by subjects receiving a transplant before a conclu-
sion on the effectiveness of a device can be determined.
Whereas transplantation is a proven therapy, there is limited
availability. Should an extracorporeal device be able to provide
sufﬁcient evidence of organ recovery, early in the timecourse of
the ALF event, it may be possible to consider a study that exam-
ines non-transplant survival as an endpoint.
Should a device be able to effectively support ALF subjects to
recovery then this would have substantial beneﬁt in freeing
organs for other recipients, as well as potentially providing cost
savings for healthcare providers. If a device were to prove effec-
tive in the treatment of ALF, then its application across the spec-
trum of other severe liver diseases would naturally be the subject
of great interest.
There are still a number of other systems in development, for
both acute and acute-on-chronic applications, which suggests
that there is a continuing interest both commercially and scien-
tiﬁcally to ﬁll this current unmet clinical need.
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